<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="ec69d365-607b-45bd-9cc8-5fea540f8b23"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PRIFTIN<sup>Â®</sup> safely and effectively. See full prescribing information for PRIFTIN. <br/>
      <br/> PRIFTIN (rifapentine) tablets, for oral use <br/> Initial U.S. Approval: 1998</title>
   <effectiveTime value="20250521"/>
   <setId root="3a64fb70-b85e-43d9-8bcd-7e893f568ae1"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="783243835" root="1.3.6.1.4.1.519.1"/>
            <name>sanofi-aventis U.S. LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="338454274" root="1.3.6.1.4.1.519.1"/>
                        <name>Sanofi S.r.l.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="441356580" root="1.3.6.1.4.1.519.1"/>
                        <name>EUROAPI ITALY SRL</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="bf4f6255-968a-4df0-981d-68d571a6a6cf"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250521"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0088-2102" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Priftin</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>rifapentine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="150" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="XJM390A33U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>RIFAPENTINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="XJM390A33U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RIFAPENTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LMI26O6933" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALUMINUM OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="S033EH8359" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ASCORBATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="AG9B65PV6B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="8" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0088-2102-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="3" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0088-2102-24" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170208"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021024" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170208"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE">
                              <originalText>dark pink</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">F</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="2293287f-025a-418d-a2b5-13f4e6ca804d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1	INDICATIONS AND USAGE</title>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item> PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by <content styleCode="italics">Mycobacterium tuberculosis</content> in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item> PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by <content styleCode="italics">M. tuberculosis </content>in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                           <item> See Full Prescribing Information for Limitations of Use. (<linkHtml href="#S1.1">1.1</linkHtml>, <linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="2bec3818-1906-488a-8296-b4cfb2052670"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Active Pulmonary Tuberculosis</title>
                     <text>
                        <paragraph>PRIFTIN<sup>Â® </sup>(rifapentine) is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by <content styleCode="italics">Mycobacterium tuberculosis</content>. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="2e7628d7-2f01-455b-b070-4bacacb9c435"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Limitations of Use</content>
                              </paragraph>
                              <paragraph>Do not use PRIFTIN monotherapy in either the initial or the continuation phases of active antituberculous treatment.</paragraph>
                              <paragraph>PRIFTIN should not be used once weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml> and <linkHtml href="#S14.1"> Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                              <paragraph>PRIFTIN has not been studied as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary tuberculosis.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="c26d1a29-1ad1-4ef2-a21d-bbfac7ac4252"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Latent Tuberculosis Infection</title>
                     <text>
                        <paragraph>PRIFTIN is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by <content styleCode="italics">Mycobacterium tuberculosis</content> in patients at high risk of progression to tuberculosis disease (including those in close contact with active tuberculosis patients, recent conversion to a positive tuberculin skin test, HIV-infected patients, or those with pulmonary fibrosis on radiograph) <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="58fb39a5-4251-480d-abac-eb6fbf52679f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Limitations of Use </content>
                              </paragraph>
                              <paragraph>Active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection.</paragraph>
                              <paragraph>PRIFTIN must always be used in combination with isoniazid as a 12-week once-weekly regimen for the treatment of latent tuberculosis infection <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>PRIFTIN in combination with isoniazid is not recommended for individuals presumed to be exposed to rifamycin-resistant or isoniazid-resistant <content styleCode="italics">M. tuberculosis</content>.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="b66200e5-a5be-4079-868d-55b762030c15"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 	DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Active pulmonary tuberculosis:</content> PRIFTIN should be used in regimens consisting of an initial 2 month phase followed by a 4 month continuation phase. (<linkHtml href="#S2.1">2.1</linkHtml>)<br/>
                              <content styleCode="bold">Initial phase (2 Months):</content> 600 mg twice weekly for two months as directly observed therapy (DOT), with no less than 72 hours between doses, in combination with other antituberculosis drugs. (<linkHtml href="#S2.1">2.1</linkHtml>)<br/>
                              <content styleCode="bold">Continuation phase (4 Months): </content>600 mg once weekly for 4 months as directly observed therapy with isoniazid or another appropriate antituberculosis agent. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <content styleCode="bold">Latent tuberculosis infection:</content> PRIFTIN should be administered in combination with isoniazid once weekly for 12 weeks as directly observed therapy. (<linkHtml href="#S2.2">2.2</linkHtml>)<br/>
                              <content styleCode="bold">Adults and children â¥12 years:</content> PRIFTIN (based on weight, see <linkHtml href="#t1">table</linkHtml> below) and isoniazid 15 mg/kg (900 mg maximum). (<linkHtml href="#S2.2">2.2</linkHtml>)<br/>
                              <content styleCode="bold">Children 2 to 11 years:</content> PRIFTIN (based on weight, see <linkHtml href="#t1">table</linkHtml> below) and isoniazid 25 mg/kg (900 mg maximum). (<linkHtml href="#S2.2">2.2</linkHtml>)<br/>
                              <table width="100%" ID="t1">
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="50%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Weight range</th>
                                       <th styleCode="Rrule">PRIFTIN dose</th>
                                       <th styleCode="Rrule">Number of PRIFTIN tablets</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">10â14 kg</td>
                                       <td styleCode="Rrule">300 mg</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">14.1â25 kg</td>
                                       <td styleCode="Rrule">450 mg</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">25.1â32 kg</td>
                                       <td styleCode="Rrule">600 mg</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">32.1â50 kg</td>
                                       <td styleCode="Rrule">750 mg</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">&gt;50 kg</td>
                                       <td styleCode="Rrule">900 mg</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <br/>For Latent Tuberculosis Infection, the maximum recommended dose of PRIFTIN is 900 mg once weekly for 12 weeks. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Take with food. Tablets may be crushed and added to semi-solid food. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="787e8d6b-421d-4737-9e48-1378ab6401ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Dosage in Active Pulmonary Tuberculosis </title>
                     <text>
                        <paragraph>PRIFTIN is only recommended for the treatment of active pulmonary tuberculosis caused by drug-susceptible organisms as part of regimens consisting of a 2-month initial phase followed by a 4-month continuation phase.</paragraph>
                        <paragraph>PRIFTIN should not be used in the treatment of active pulmonary tuberculosis caused by rifampin-resistant strains.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="f662cb9e-2181-4f24-b93e-fc4a60dcb31a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Initial phase (2 Months): </content>PRIFTIN should be administered at a dose of 600 mg twice weekly for two months as directly observed therapy (DOT), with an interval of no less than 3 consecutive days (72 hours) between doses, in combination with other antituberculosis drugs as part of an appropriate regimen which includes daily companion drugs such as isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA).</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2db2eaf4-6819-46bd-9f76-74364c9a891f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Continuation phase (4 Months):</content> Following the initial phase (2 months), continuation phase (4 months) treatment consists of PRIFTIN 600 mg once weekly for 4 months in combination with isoniazid or another appropriate antituberculosis agent for susceptible organisms administered as directly observed therapy.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="efac238b-3e8e-46a3-92eb-78ebba59fb3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage in Latent Tuberculosis Infection</title>
                     <text>
                        <paragraph>PRIFTIN should be administered once weekly in combination with isoniazid for 12 weeks as directly observed therapy.	</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="41aaf44d-adc5-4ea7-8353-f684c1d271c2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Adults and children 12 years and older:</content> The recommended dose of PRIFTIN should be determined based on weight of the patient up to a maximum of 900 mg once weekly (see <linkHtml href="#table1">Table 1</linkHtml>). The recommended dose of isoniazid is 15 mg/kg (rounded to the nearest 50 mg or 100 mg) up to a maximum of 900 mg once weekly for 12 weeks. 										</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="83a6fd56-c94f-43d8-af68-907a3579b898"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Children 2 to 11 years:</content> The recommended dose of PRIFTIN should be determined based on weight of the patient up to a maximum of 900 mg once weekly (see <linkHtml href="#table1">Table 1</linkHtml>). The recommended dose of isoniazid is 25 mg/kg (rounded to the nearest 50 mg or 100 mg) up to a maximum of 900 mg once weekly for 12 weeks. 										</paragraph>
                              <table width="75%" ID="table1">
                                 <caption>Table 1: Weight Based Dose of PRIFTIN in the Treatment of Latent Tuberculosis Infection</caption>
                                 <col width="34%" align="center" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <col width="32%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th valign="middle" styleCode="Lrule Rrule">Weight range</th>
                                       <th valign="middle" styleCode="Rrule">PRIFTIN dose</th>
                                       <th valign="middle" styleCode="Rrule">Number of PRIFTIN tablets</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">10â14 kg</td>
                                       <td styleCode="Rrule">300 mg</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">14.1â25 kg</td>
                                       <td styleCode="Rrule">450 mg</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">25.1â32 kg</td>
                                       <td styleCode="Rrule">600 mg</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">32.1â50 kg</td>
                                       <td styleCode="Rrule">750 mg</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">&gt;50 kg</td>
                                       <td styleCode="Rrule">900 mg</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="00530f94-f077-4073-9195-d735e6159580"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Administration</title>
                     <text>
                        <paragraph>Take PRIFTIN with meals. Administration of PRIFTIN with a meal increases oral bioavailability and may reduce the incidence of gastrointestinal upset, nausea, and/or vomiting <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>For patients who cannot swallow tablets, the tablets may be crushed and added to a small amount of semi-solid food, all of which should be consumed immediately <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="d2a1b350-9df9-4250-a0bf-5eceb143aaf1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>PRIFTIN is supplied as 150 mg round normal convex dark-pink film-coated tablets debossed "F" on one side of tablet.</paragraph>
               </text>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>150 mg tablets (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="c0d35c53-43ab-4f63-aa79-8bc88078919e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 	CONTRAINDICATIONS</title>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to any rifamycin. (<linkHtml href="#S4.1">4.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="4774b079-0afe-49ac-b574-6fb407eb0b6c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1	Hypersensitivity</title>
                     <text>
                        <paragraph>PRIFTIN is contraindicated in patients with a history of hypersensitivity to rifamycins.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="7b5f8123-791c-4995-832b-ae132db6e27e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item> Hepatotoxicity: Monitor for symptoms of liver injury and discontinue PRIFTIN if signs or symptoms or liver injury occur. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item> Hypersensitivity: Discontinue PRIFTIN if signs or symptoms of hypersensitivity reaction occur. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Severe cutaneous adverse reactions: Discontinue PRIFTIN at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item> Relapse in the treatment of active pulmonary tuberculosis: Do not use as a once-weekly continuation phase regimen with isoniazid in HIV-infected patients. Monitor for signs or symptoms of relapse in patients with cavitary lesions or bilateral disease. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S14.1">14.1</linkHtml>)</item>
                           <item> Drug Interactions: May interact with drugs metabolized by CYP450. (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S7.4">7.4</linkHtml>)</item>
                           <item> Discoloration of body fluids:  May permanently stain contact lenses or dentures red-orange. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>âassociated diarrhea: Evaluate if diarrhea occurs. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>Porphyria: Avoid use in patients with porphyria. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="b4d63a90-e52b-4bbb-83c0-830aa67db1b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Hepatotoxicity</title>
                     <text>
                        <paragraph>Elevations of liver transaminases may occur in patients receiving PRIFTIN <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Patients on PRIFTIN should be monitored for symptoms of liver injury.</paragraph>
                        <paragraph>Patients with abnormal liver tests and/or liver disease or patients initiating treatment for active pulmonary tuberculosis should only be given PRIFTIN in cases of necessity and under strict medical supervision. In such patients, obtain serum transaminase levels prior to therapy and every 2 to 4 weeks while on therapy. Discontinue PRIFTIN if evidence of liver injury occurs.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="50bc956e-b473-47e5-b53f-a9fad4985c51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Hypersensitivity and Related Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions may occur in patients receiving PRIFTIN. Signs and symptoms of these reactions may include hypotension, urticaria, angioedema, acute bronchospasm, conjunctivitis, thrombocytopenia, neutropenia or flu-like syndrome (weakness, fatigue, muscle pain, nausea, vomiting, headache, fever, chills, aches, rash, itching, sweats, dizziness, shortness of breath, chest pain, cough, syncope, palpitations). There have been reports of anaphylaxis <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                        <paragraph>Monitor patients receiving PRIFTIN therapy for signs and/or symptoms of hypersensitivity reactions. If these symptoms occur, administer supportive measures and discontinue PRIFTIN.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="1f4dcd8f-48ec-47f6-b60a-00002aa82daf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Severe Cutaneous Adverse Reactions</title>
                     <text>
                        <paragraph>Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome have been reported in association with the use of rifapentine (PRIFTIN) treatment regimens in patients with active and latent tuberculosis. Discontinue PRIFTIN at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="5ae28474-aa9b-4280-b7c5-cfa71fec1595"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 	Relapse in the Treatment of Active Pulmonary Tuberculosis</title>
                     <text>
                        <paragraph>PRIFTIN has not been evaluated as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary TB.</paragraph>
                        <paragraph>Do not use PRIFTIN as a once-weekly continuation phase regimen in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin-resistant organisms <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Higher relapse rates may occur in patients with cavitary pulmonary lesions and/or positive sputum cultures after the initial phase of active tuberculosis treatment and in patients with evidence of bilateral pulmonary disease. Monitor for signs and symptoms of TB relapse in these patients <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Poor adherence to therapy is associated with high relapse rate. Emphasize the importance of compliance with therapy <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="c49bbc57-321b-4e2a-a734-bba1234282a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 	Drug Interactions</title>
                     <text>
                        <paragraph>Rifapentine is an inducer of CYP450 enzymes. Concomitant use of rifapentine with other drugs metabolized by these enzymes, such as protease inhibitors, certain reverse transcriptase inhibitors, and hormonal contraception may cause a significant decrease in plasma concentrations and loss of therapeutic effect <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>, <linkHtml href="#S7.3">7.3</linkHtml>, <linkHtml href="#S7.4">7.4)</linkHtml>
                           </content> and<content styleCode="italics">
                              <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="3cb29181-5336-4a62-974b-9568e6e21cab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 	Discoloration of Body Fluids</title>
                     <text>
                        <paragraph>PRIFTIN may produce a red-orange discoloration of body tissues and/or fluids (e.g., skin, teeth, tongue, urine, feces, saliva, sputum, tears, sweat, and cerebrospinal fluid). Contact lenses or dentures may become permanently stained.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="46baeeb8-6791-47a9-b4c3-78a03434f98f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Clostridioides DifficileâAssociated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>âassociated diarrhea (CDAD) has been reported with the use of nearly all systemic antibacterial agents, including PRIFTIN, with severity ranging from mild diarrhea to fatal colitis. Treatment with antibacterial agents can alter the normal flora of the colon and may permit overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, discontinue antibacterial use not directed against <content styleCode="italics">C. difficile</content> if possible. Institute appropriate measures such as fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="3e2aa1bd-146e-4512-bfa6-0fb7fc78df3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Porphyria</title>
                     <text>
                        <paragraph>Porphyria has been reported in patients receiving rifampin, attributed to induction of delta amino levulinic acid synthetase. Because PRIFTIN may have similar enzyme induction properties, avoid the use of PRIFTIN in patients with porphyria.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="ab26442f-b15d-4ad1-abd5-5b3cb5223a54"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Severe Cutaneous Adverse Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Discoloration of Body Fluids <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridioides Difficile</content>âAssociated Diarrhea <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Porphyria <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions with regimen for active pulmonary tuberculosis (3% and greater) are anemia, lymphopenia, hemoptysis, neutropenia, cough, thrombocytosis, increased sweating, increased ALT, increased AST, back pain, rash, anorexia, arthralgia, increased blood urea, and headache. The most common adverse reaction (3% and greater) with the regimen for latent tuberculosis infection is hypersensitivity reaction. (<linkHtml href="#S6.1">6.1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="8150c8f8-d702-4975-b018-9d9b28f0fcb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="b8d935b1-0f2c-45c1-ba73-857ac326389e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Active Pulmonary Tuberculosis</content>
                              </paragraph>
                              <paragraph>PRIFTIN was studied in a randomized, open label, active-controlled trial of HIV-negative patients with active pulmonary tuberculosis. The population consisted primarily of male subjects with a mean age of 37 Â± 11 years. In the initial 2-month phase of treatment, 361 patients received PRIFTIN 600 mg twice a week in combination with daily isoniazid, pyrazinamide, and ethambutol and 361 subjects received rifampin in combination with isoniazid, pyrazinamide and ethambutol all administered daily. Ethambutol was discontinued when drug susceptibly testing was known. During the 4-month continuation phase, 317 patients in the PRIFTIN group continued to receive PRIFTIN 600 mg dosed once weekly with isoniazid and 304 patients in the rifampin group received twice weekly rifampin and isoniazid. Both treatment groups received pyridoxine (Vitamin B6) over the 6-month treatment period.</paragraph>
                              <paragraph>Because PRIFTIN was administered as part of a combination regimen, the adverse reaction profile reflects the entire regimen.</paragraph>
                              <paragraph>Twenty-two deaths occurred in the study, eleven in the rifampin combination therapy group and eleven in the PRIFTIN combination therapy group. 18/361 (5%) rifampin combination therapy patients discontinued the study due to an adverse reaction compared to 11/361 (3%) PRIFTIN combination therapy patients. Three patients (two rifampin combination therapy patients and one PRIFTIN combination therapy patient) were discontinued in the initial phase due to hepatotoxicity. Concomitant medications for all three patients included isoniazid, pyrazinamide, ethambutol, and pyridoxine. All three recovered without sequelae.</paragraph>
                              <paragraph>Five patients had adverse reactions associated with PRIFTIN overdose. These reactions included hematuria, neutropenia, hyperglycemia, ALT increased, hyperuricemia, pruritus, and arthritis.</paragraph>
                              <paragraph>Table 2 presents selected treatment-emergent adverse reactions associated with the treatment regimens which occurred in at least 1% of patients during treatment and post treatment through the first three months of follow-up.</paragraph>
                              <table width="90%" ID="table2">
                                 <caption>Table 2: Selected Treatment Emergent Adverse Reactions during Treatment of Active Pulmonary Tuberculosis and through Three Months Follow-up</caption>
                                 <col width="27%" align="left" valign="top"/>
                                 <col width="21%" align="center" valign="middle"/>
                                 <col width="16%" align="center" valign="middle"/>
                                 <col width="21%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Botrule Rrule" colspan="2" valign="top">Initial Phase<footnote ID="t2f1">Initial phase consisted of therapy with either PRIFTIN twice weekly or rifampin daily combined with daily isoniazid, pyrazinamide, and ethambutol for 60 days.</footnote>
                                       </th>
                                       <th styleCode="Botrule Rrule" colspan="2">Continuation Phase<footnote ID="t2f2">Continuation phase consisted of therapy with either PRIFTIN once weekly or rifampin twice weekly combined with daily isoniazid for 120 days.</footnote>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="middle">System Organ Class<br/>Adverse Reaction</th>
                                       <th styleCode="Rrule">PRIFTIN Combination<br/>(N=361)<br/>N (%)</th>
                                       <th styleCode="Rrule">Rifampin Combination<br/>(N=361)<br/>N (%)</th>
                                       <th styleCode="Rrule">PRIFTIN Combination<br/>(N=317)<br/>N (%)</th>
                                       <th styleCode="Rrule">Rifampin Combination<br/>(N=304)<br/>N (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Blood and lymphatics</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anemia</td>
                                       <td styleCode="Rrule">41 (11.4)</td>
                                       <td styleCode="Rrule">41 (11.4)</td>
                                       <td styleCode="Rrule">5 (1.6)</td>
                                       <td styleCode="Rrule">10 (3.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Lymphopenia</td>
                                       <td styleCode="Rrule">38 (10.5)</td>
                                       <td styleCode="Rrule">37 (10.2)</td>
                                       <td styleCode="Rrule">10 (3.2)</td>
                                       <td styleCode="Rrule">9 (3.0)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Neutropenia</td>
                                       <td styleCode="Rrule">22 (6.1)</td>
                                       <td styleCode="Rrule">21 (5.8)</td>
                                       <td styleCode="Rrule">27 (8.5)</td>
                                       <td styleCode="Rrule">24 (7.9)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Leukocytosis</td>
                                       <td styleCode="Rrule">6 (1.7)</td>
                                       <td styleCode="Rrule">13 (3.6)</td>
                                       <td styleCode="Rrule">5 (1.6)</td>
                                       <td styleCode="Rrule">2 (0.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Thrombocytosis</td>
                                       <td styleCode="Rrule">20 (5.5)</td>
                                       <td styleCode="Rrule">13 (3.6)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                       <td styleCode="Rrule">0 (0.0)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Thrombocytopenia</td>
                                       <td styleCode="Rrule">6 (1.7)</td>
                                       <td styleCode="Rrule">6 (1.7)</td>
                                       <td styleCode="Rrule">4 (1.3)</td>
                                       <td styleCode="Rrule">6 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Lymphadenopathy</td>
                                       <td styleCode="Rrule">4 (1.1)</td>
                                       <td styleCode="Rrule">2 (0.6)</td>
                                       <td styleCode="Rrule">0 (0.0)</td>
                                       <td styleCode="Rrule">2 (0.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Eye</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Conjunctivitis</td>
                                       <td styleCode="Rrule">8 (2.2)</td>
                                       <td styleCode="Rrule">2 (0.6)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Gastrointestinal</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspepsia</td>
                                       <td styleCode="Rrule">6 (1.7)</td>
                                       <td styleCode="Rrule">11 (3)</td>
                                       <td styleCode="Rrule">4 (1.3)</td>
                                       <td styleCode="Rrule">6 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">6 (1.7)</td>
                                       <td styleCode="Rrule">14 (3.9)</td>
                                       <td styleCode="Rrule">3 (0.9)</td>
                                       <td styleCode="Rrule">3 (1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">7 (1.9)</td>
                                       <td styleCode="Rrule">3 (0.8)</td>
                                       <td styleCode="Rrule">2 (0.6)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">5 (1.4)</td>
                                       <td styleCode="Rrule">2 (0.6)</td>
                                       <td styleCode="Rrule">2 (0.6)</td>
                                       <td styleCode="Rrule">0 (0.0)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">General</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Back Pain</td>
                                       <td styleCode="Rrule">15 (4.2)</td>
                                       <td styleCode="Rrule">11 (3)</td>
                                       <td styleCode="Rrule">11 (3.5)</td>
                                       <td styleCode="Rrule">4 (1.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal Pain</td>
                                       <td styleCode="Rrule">3 (0.8)</td>
                                       <td styleCode="Rrule">3 (0.8)</td>
                                       <td styleCode="Rrule">4 (1.3)</td>
                                       <td styleCode="Rrule">4 (1.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fever</td>
                                       <td styleCode="Rrule">5 (1.4)</td>
                                       <td styleCode="Rrule">7 (1.9)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anorexia</td>
                                       <td styleCode="Rrule">14 (3.9)</td>
                                       <td styleCode="Rrule">18 (5)</td>
                                       <td styleCode="Rrule">8 (2.5)</td>
                                       <td styleCode="Rrule">6 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Hepatic and biliary</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ALT Increased</td>
                                       <td styleCode="Rrule">18 (5)</td>
                                       <td styleCode="Rrule">23 (6.4)</td>
                                       <td styleCode="Rrule">7 (2.2)</td>
                                       <td styleCode="Rrule">10 (3.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AST Increased</td>
                                       <td styleCode="Rrule">15 (4.2)</td>
                                       <td styleCode="Rrule">18 (5)</td>
                                       <td styleCode="Rrule">7 (2.2)</td>
                                       <td styleCode="Rrule">8 (2.6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Investigations</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood urea increased</td>
                                       <td styleCode="Rrule">4 (1.1)</td>
                                       <td styleCode="Rrule">3 (0.8)</td>
                                       <td styleCode="Rrule">10 (3.2)</td>
                                       <td styleCode="Rrule">15 (4.9)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Musculoskeletal</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Arthralgia</td>
                                       <td styleCode="Rrule">13 (3.6)</td>
                                       <td styleCode="Rrule">13 (3.6)</td>
                                       <td styleCode="Rrule">3 (0.9)</td>
                                       <td styleCode="Rrule">5 (1.6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Neurologic</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">11 (3)</td>
                                       <td styleCode="Rrule">13 (3.6)</td>
                                       <td styleCode="Rrule">3 (0.9)</td>
                                       <td styleCode="Rrule">7 (2.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">5 (1.4)</td>
                                       <td styleCode="Rrule">5 (1.4)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Respiratory</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hemoptysis</td>
                                       <td styleCode="Rrule">27 (7.5)</td>
                                       <td styleCode="Rrule">20 (5.5)</td>
                                       <td styleCode="Rrule">6 (1.9)</td>
                                       <td styleCode="Rrule">6 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Coughing</td>
                                       <td styleCode="Rrule">21 (5.8)</td>
                                       <td styleCode="Rrule">8 (2.2)</td>
                                       <td styleCode="Rrule">9 (2.8)</td>
                                       <td styleCode="Rrule">11 (3.6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule">
                                          <content styleCode="bold">Skin</content>
                                       </td>
                                       <td/>
                                       <td/>
                                       <td/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash</td>
                                       <td styleCode="Rrule">15 (4.2)</td>
                                       <td styleCode="Rrule">26 (7.2)</td>
                                       <td styleCode="Rrule">8 (2.5)</td>
                                       <td styleCode="Rrule">8 (2.6)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sweating Increased</td>
                                       <td styleCode="Rrule">19 (5.3)</td>
                                       <td styleCode="Rrule">18 (5)</td>
                                       <td styleCode="Rrule">5 (1.6)</td>
                                       <td styleCode="Rrule">4 (1.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">10 (2.8)</td>
                                       <td styleCode="Rrule">16 (4.4)</td>
                                       <td styleCode="Rrule">3 (0.9)</td>
                                       <td styleCode="Rrule">0 (0.0)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Rash Maculopapular</td>
                                       <td styleCode="Rrule">6 (1.7)</td>
                                       <td styleCode="Rrule">3 (0.8)</td>
                                       <td styleCode="Rrule">0 (0.0)</td>
                                       <td styleCode="Rrule">1 (0.3)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The following selected treatment-emergent adverse reactions were reported in less than 1% of the PRIFTIN combination therapy patients during treatment and post treatment through the first three months of follow-up.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Blood and Lymphatics:</content> lymphocytosis, hematoma, purpura, thrombosis.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cardiovascular: </content>syncope, tachycardia, palpitation, orthostatic hypotension, pericarditis.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Metabolic &amp; Nutritional:</content> alkaline phosphatase increased.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Gastrointestinal:</content> gastritis, esophagitis, pancreatitis, salivary gland enlargement.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">General:</content> asthenia, facial edema.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Hepatobiliary:</content> bilirubinemia, hepatomegaly, jaundice.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Infectious Disease:</content> infection fungal.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Musculoskeletal:</content> myalgia, myositis.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Neurologic:</content> somnolence, dysphonia.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Pregnancy, Puerperium and Perinatal Conditions:</content> abortion.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Psychiatric:</content> anxiety, confusion.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Reproductive Disorders:</content> vaginitis, vaginal hemorrhage, leukorrhea.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Respiratory:</content> dyspnea, pneumonitis, pulmonary fibrosis, asthma, bronchospasm, laryngeal edema, laryngitis.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Skin:</content> urticaria, skin discoloration.</paragraph>
                              <paragraph>In another randomized, open-label trial, 1075 HIV non-infected and infected patients with active pulmonary tuberculosis who had completed an initial 2-month phase of treatment with 4 drugs were randomly assigned to receive either PRIFTIN 600 mg and isoniazid once weekly or rifampin and isoniazid twice weekly for the 4-month continuation phase. Five hundred and two nonâHIV-infected and 36 HIV-infected patients were randomized to receive the PRIFTIN regimen and 502 HIV-noninfected and 35 HIV-infected patients were randomized to receive the rifampin regimen.</paragraph>
                              <paragraph>The death rate was 6.5% for the PRIFTIN combination regimen compared to 6.7% for the rifampin combination regimen.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e0d34733-0dc6-4633-9298-86ebe938357d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Latent Tuberculosis Infection</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                           <component>
                              <section>
                                 <id root="accaafde-c9e8-4671-81bc-78b777234444"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Main study</paragraph>
                                    <paragraph>PRIFTIN in combination with isoniazid given once weekly for 3 months (3RPT/INH) was compared to isoniazid given once daily for 9 months (9INH) in an open-label, randomized trial in patients with a positive tuberculin skin test, and at high risk for progression from latent tuberculosis infection to active tuberculosis disease. PRIFTIN was dosed by weight, and isoniazid mg/kg dose was determined according to age<content styleCode="italics"> [see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>] </content>to a maximum of 900 mg each.</paragraph>
                                    <paragraph>A total of 4040 patients received at least one dose of the 3RPT/INH regimen, including 348 children 2 to 17 years of age and 105 HIV-infected individuals. A total of 3759 received at least one dose of the 9INH regimen, including 342 children 2 to 17 years of age and 95 HIV-infected individuals.</paragraph>
                                    <paragraph>Patients were followed for 33 months from the time of enrollment. Treatment-emergent adverse reactions were defined as those occurring during treatment and 60 days after the last dose of treatment. One hundred and sixty-one (4%) 3RPT/INH subjects had a rifamycin hypersensitivity reaction, defined as either: a) one of the following: hypotension, urticaria, angioedema, acute bronchospasm, or conjunctivitis occurring in relation to study drug or b) at least four of the following symptoms occurring in relation to the study drug, with at least one symptom being CTCAE Grade 2 or higher: weakness, fatigue, nausea, vomiting, headache, fever, aches, sweats, dizziness, shortness of breath, flushing or chills. No specific definition was used for isoniazid hypersensitivity; 18 (0.5%) 9INH subjects were classified as having a hypersensitivity reaction. Hepatotoxicity was defined as AST â¥3 Ã upper limit of normal in the presence of specific signs and symptoms of hepatitis, or AST &gt;5 Ã upper limit of normal regardless of signs or symptoms. One hundred and thirteen (3%) 9INH subjects and 24 (0.6%) 3RPT/INH subjects developed hepatotoxicity.</paragraph>
                                    <paragraph>One hundred and ninety-six subjects (4.9%) in the 3RPT/INH arm discontinued treatment due to a treatment related adverse reaction patients and 142 (3.8%) in the 9INH arm discontinued treatment due to a treatment related adverse reaction. In the 3RPT/INH group, the most frequent treatment related adverse reaction resulting in treatment discontinuation was hypersensitivity reaction, occurring in 120 (3%) patients. In the 9INH group, the most frequent treatment related adverse reaction resulting in treatment discontinuation was hepatotoxicity, occurring in 76 (2%) patients.</paragraph>
                                    <paragraph>Seventy-one deaths occurred, 31/4040, 0.77% in the 3RPT/INH group and 40/3759 (1.06%) in the 9INH group) during the 33-month study period. During the treatment emergent period, 11 deaths occurred, 4 in the 3RPT/INH group and 7 in the 9INH group. None of the reported deaths were considered related to treatment with study drugs or were attributed to tuberculosis disease.</paragraph>
                                    <paragraph>Table 3 presents select adverse reactions that occurred during the treatment emergent period in the main study in LTBI patients treated with 3RPT/INH or 9INH at a frequency greater than 0.5%.</paragraph>
                                    <table width="90%" ID="table3">
                                       <caption>Table 3: Select Adverse Reactions Occurring in 0.5% or Greater of Patients<footnote ID="t3f1">Includes events reported through 60 days after last dose of study drug.</footnote> in the Latent Tuberculosis Infection Main Study</caption>
                                       <col width="40%" align="left" valign="bottom"/>
                                       <col width="30%" align="center" valign="bottom"/>
                                       <col width="30%" align="center" valign="bottom"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">System Organ Class<br/>Adverse Reaction</th>
                                             <th styleCode="Rrule">3RPT/INH<br/>(N=4040)<br/>N (%)</th>
                                             <th styleCode="Rrule">9INH<br/>(N=3759)<br/>N (%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Immune system disorders</content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hypersensitivity</td>
                                             <td styleCode="Rrule">161 (4)</td>
                                             <td styleCode="Rrule">18 (0.5)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Hepatobiliary disorders</content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hepatitis</td>
                                             <td styleCode="Rrule">24 (0.6)</td>
                                             <td styleCode="Rrule">113 (3)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Nervous system disorders</content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Headache</td>
                                             <td styleCode="Rrule">26 (0.6)</td>
                                             <td styleCode="Rrule">17 (0.5)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                             <td styleCode="Rrule"/>
                                             <td styleCode="Rrule"/>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Â Â Skin reaction</td>
                                             <td styleCode="Rrule">31 (0.8)</td>
                                             <td styleCode="Rrule">21 (0.6)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="611a6caf-f801-410d-8cfc-7167738ed401"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Pediatric substudy</paragraph>
                                    <paragraph>Six hundred and ninety children 2 to 17 years of age received at least one dose of study drugs in the main study. An additional 342 children 2 to 17 years of age received at least one dose in the pediatric extension study (total 1032 children; 539 received 3RPT/INH and 493 received 9INH).</paragraph>
                                    <paragraph>No children in either treatment arm developed hepatotoxicity. Using the same definition for rifamycin hypersensitivity reaction as in the main study, 7 (1.3%) of children in the 3RPT/INH group experienced a rifamycin hypersensitivity reaction. Adverse reactions in children 2 to 11 years of age and 12 to 17 years of age were similar. </paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1e36fb06-e8fc-4af2-b4af-963d37f26f50"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>HIV substudy</paragraph>
                                    <paragraph>Two hundred HIV-infected patients with latent tuberculosis infection received at least one dose of study drugs in the main study and an additional 193 patients received at least one dose in the extension study (total of 393; 207 received 3RPT/INH and 186 received 9INH). Compared to the HIV-negative patients enrolled in the main study, a higher proportion of HIV-infected patients in each treatment arm experienced a treatment emergent adverse reaction, including a higher incidence of hepatotoxicity. Hepatotoxicity occurred in 3/207 (1.5%) patients in the 3RPT/INH arm and in 14/186 (7.5%) in the 9INH arm. Rifamycin hypersensitivity occurred in only one HIV-infected patient.</paragraph>
                                    <paragraph>Eleven deaths occurred during the 33-month follow up period (6/207 in the 3RPT/INH group and 5/186 in the 9INH group) including one death in the 9INH arm during the treatment emergent period. None of the reported deaths were considered related to treatment with study drugs or tuberculosis disease.</paragraph>
                                    <paragraph>Selected treatment-emergent adverse reactions reported during treatment and 60 days post treatment in less than 0.5% of the 3RPT/INH combination-therapy group in the main study are presented below by body system.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Eye Disorders: </content>conjunctivitis.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Blood and Lymphatic System Disorders:</content> leukopenia, anemia, lymphadenopathy, neutropenia.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal Disorders:</content> nausea, diarrhea, vomiting, abdominal pain, constipation, dry mouth, dyspepsia, esophageal irritation, gastritis, pancreatitis.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">General Disorders and Administration Site Conditions: </content>fatigue, pyrexia, asthenia, chest pain, chills, feeling jittery.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Infections and Infestations:</content> pharyngitis, viral infection, vulvovaginal candidiasis.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Metabolism and Nutrition Disorders: </content>hyperglycemia, gout, hyperkalemia, decreased appetite, hyperlipidemia.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders: </content>arthralgia, myalgia, back pain, rhabdomyolysis.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Nervous System Disorders:</content> dizziness, convulsion, paresthesia, headache, neuropathy peripheral, syncope.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric Disorders:</content> depression, anxiety, disorientation, suicidal ideation.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Renal and Urinary Disorders: </content>azotemia.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Reproductive System and Breast Disorders:</content> vulvovaginal pruritus.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders: </content>cough, dyspnea, oropharyngeal pain, asthma, bronchial hyperactivity, epistaxis.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Skin and Subcutaneous Tissue Disorders: </content>rash, hyperhidrosis, pruritus, urticaria.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="53a9e36c-57ba-49f1-8d14-8a2ba4a836f0"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified from postmarketing surveillance of rifapentine. Because these reactions are reported from a population of unknown size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="0adb8f39-6a89-4472-8048-088bd1af0e57"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Skin and subcutaneous tissue disorders:</content> Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="99141a92-90e9-40a9-8c3c-00bc324fc255"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7	 DRUG INTERACTIONS</title>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item> Protease Inhibitors and Reverse Transcriptase Inhibitors. (<linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item> Hormonal Contraceptives: Use an effective non-hormonal method of contraception or add a barrier method of contraception during treatment with PRIFTIN. (<linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item> May increase metabolism and decrease the activity of drugs metabolized by cytochrome P450 3A4 and 2C8/9. Dosage adjustments may be necessary if given concomitantly. (<linkHtml href="#S7.4">7.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="5e3e9a10-6bb1-455a-a95e-0f30dac10b98"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 	Protease Inhibitors and Reverse Transcriptase Inhibitors</title>
                     <text>
                        <paragraph>Rifapentine is an inducer of CYP450 enzymes. Concomitant use of PRIFTIN with other drugs metabolized by these enzymes, such as protease inhibitors and certain reverse transcriptase inhibitors, may cause a significant decrease in plasma concentrations and loss of therapeutic effect of the protease inhibitor or reverse transcriptase inhibitor <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>
                           </content> and<content styleCode="italics">
                              <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="31beb006-003e-48c4-ac6e-098c0b15e4e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 	Fixed-Dose Combination of Efavirenz, Emtricitabine, and Tenofovir</title>
                     <text>
                        <paragraph>Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine, and tenofovir. No clinically significant change in CD4 cell counts or viral loads were noted <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="07ad7cbc-6dc1-44a0-9592-9c465bb00408"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 	Hormonal Contraceptives</title>
                     <text>
                        <paragraph>PRIFTIN may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method or add a barrier method of contraception during treatment with PRIFTIN <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="0402c430-bdfb-414b-af62-336c9f92b388"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 	Cytochrome P450 3A4 and 2C8/9</title>
                     <text>
                        <paragraph>Rifapentine is an inducer of cytochromes P450 3A4 and P450 2C8/9. Therefore, PRIFTIN may increase the metabolism of other coadministered drugs that are metabolized by these enzymes. Induction of enzyme activities by PRIFTIN occurred within 4 days after the first dose. Enzyme activities returned to baseline levels 14 days after discontinuing PRIFTIN.</paragraph>
                        <paragraph>Rifampin has been reported to accelerate the metabolism and may reduce the activity of the following drugs; hence, PRIFTIN may also increase the metabolism and decrease the activity of these drugs. Dosage adjustments of the drugs in Table 4 or of other drugs metabolized by cytochrome P450 3A4 or P450 2C8/9 may be necessary if they are given concurrently with PRIFTIN.</paragraph>
                        <table width="100%" ID="table4">
                           <caption>Table 4: Drug Interactions with PRIFTIN: Dosage Adjustment May be Necessary</caption>
                           <col width="50%" align="center" valign="top"/>
                           <col width="50%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Drug Class</th>
                                 <th styleCode="Rrule">Examples of Drugs Within Class 											</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antiarrhythmics</td>
                                 <td styleCode="Rrule">Disopyramide, mexiletine, quinidine, tocainide</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antibiotics</td>
                                 <td styleCode="Rrule">Chloramphenicol, clarithromycin, dapsone, doxycycline;<br/> Fluoroquinolones (such as ciprofloxacin)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Oral Anticoagulants</td>
                                 <td styleCode="Rrule">Warfarin</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Anticonvulsants</td>
                                 <td styleCode="Rrule">Phenytoin</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antimalarials</td>
                                 <td styleCode="Rrule">Quinine</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Azole Antifungals</td>
                                 <td styleCode="Rrule">Fluconazole, itraconazole, ketoconazole</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antipsychotics</td>
                                 <td styleCode="Rrule">Haloperidol</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Barbiturates</td>
                                 <td styleCode="Rrule">Phenobarbital</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Benzodiazepines</td>
                                 <td styleCode="Rrule">Diazepam</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Beta-Blockers</td>
                                 <td styleCode="Rrule">Propranolol</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Calcium Channel Blockers</td>
                                 <td styleCode="Rrule">Diltiazem, nifedipine, verapamil</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Cardiac Glycoside Preparations</td>
                                 <td styleCode="Rrule">Digoxin</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Corticosteroids</td>
                                 <td styleCode="Rrule">Prednisone</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Fibrates</td>
                                 <td styleCode="Rrule">Clofibrate</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Oral Hypoglycemics</td>
                                 <td styleCode="Rrule">Sulfonylureas (e.g., glyburide, glipizide)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hormonal Contraceptives/Progestins</td>
                                 <td styleCode="Rrule">Ethinyl estradiol, levonorgestrel</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Immunosuppressants</td>
                                 <td styleCode="Rrule">Cyclosporine, tacrolimus</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Methylxanthines</td>
                                 <td styleCode="Rrule">Theophylline</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Narcotic analgesics</td>
                                 <td styleCode="Rrule">Methadone</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Phosphodiesterase-5 (PDE-5) Inhibitors</td>
                                 <td styleCode="Rrule">Sildenafil</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Thyroid preparations</td>
                                 <td styleCode="Rrule">Levothyroxine</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Tricyclic antidepressants</td>
                                 <td styleCode="Rrule">Amitriptyline, nortriptyline</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="943557ef-f4d9-42fa-a09e-4de9aa944301"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5	Other Interactions</title>
                     <text>
                        <paragraph>The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. There is minimal potential for PRIFTIN metabolism to be inhibited or induced by another drug, based upon the characteristics of the esterase enzymes.</paragraph>
                        <paragraph>Since PRIFTIN is highly bound to albumin, drug displacement interactions may also occur <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="8d816def-21dd-4577-918d-f91d8b52811a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6	Interactions with Laboratory Tests</title>
                     <text>
                        <paragraph>Therapeutic concentrations of rifampin have been shown to inhibit standard microbiological assays for serum folate and Vitamin B<sub>12</sub>. Similar drug-laboratory interactions should be considered for PRIFTIN; thus, alternative assay methods should be considered.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="72c7605d-1f8a-49a5-aedc-869477ebae92"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250521"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item> Pregnancy: Based on animal data, may cause fetal harm. (<linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Lactation: Monitor infants exposed to PRIFTIN through breast milk for irritability, prolonged unexplained crying, yellowing of the eyes, changes in color of the urine or stool. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                           <item> Pediatrics: Safety and effectiveness in treating active pulmonary tuberculosis in children under the age of 12 years have not been established. (<linkHtml href="#S8.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="2d21426c-ddcd-4e46-b1a8-d20b59ee6051"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 	Pregnancy</title>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="bf6a7e02-8a4c-4d84-88c0-0d202446dcbd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on animal data, PRIFTIN may cause fetal harm when administered to a pregnant woman. Available data from clinical trials, case reports, epidemiology studies and postmarketing experience with PRIFTIN use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, adverse maternal or fetal outcomes. In two clinical trials, a total of 59 patients who were treated with rifapentine in combination with other anti-tuberculosis drugs became pregnant. Overall, the reported rate of miscarriage following rifapentine exposure in these two clinical trials did not represent an increase over the background rate of miscarriage reported in the general population <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. There are risks associated with active tuberculosis during pregnancy. When administered during the last few weeks of pregnancy, PRIFTIN may be associated with maternal postpartum hemorrhage and bleeding in the exposed neonates <content styleCode="italics">(see <linkHtml href="#CC">Clinical Considerations</linkHtml>)</content>. In animal reproduction and developmental toxicity studies, adverse developmental outcomes (including cleft palate or mal-positioned aortic arches) were observed following administration of rifapentine to pregnant rats and rabbits at doses approximately 0.6 and 0.3 to 1.3 times, respectively, of the recommended human dose based on body surface area comparisons <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. Based on animal data, advise pregnant women of the risk for fetal harm. As rifapentine is always used in combination with other antituberculosis drugs such as isoniazid, ethambutol, and pyrazinamide, refer to the prescribing information of the other drug(s) for more information on their associated risks of use during pregnancy.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%â4% and 15%â20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="e457609f-5d4c-4fd4-8861-a3fe2eb0edea"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                           <component>
                              <section>
                                 <id root="ad2e8eb3-81f7-4f4c-8713-9e935daa862e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Disease-associated maternal and/or embryo-fetal risk</paragraph>
                                    <paragraph>Active tuberculosis in pregnancy is associated with adverse maternal and neonatal outcomes including maternal anemia, cesarean delivery, preterm birth, low birth weight, birth asphyxia, and perinatal infant death.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="803e1414-0e19-4b65-b6b6-1b5b37c2134a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Labor or delivery</paragraph>
                                    <paragraph>When administered during the last few weeks of pregnancy, PRIFTIN may increase the risk for maternal postpartum hemorrhage and bleeding in the exposed neonate. Monitor prothrombin time of pregnant women and neonates who are exposed to PRIFTIN during the last few weeks of pregnancy. Treatment with Vitamin K may be indicated.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="3089bf4d-31ef-475a-84f6-5ada7748dc1b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                           <component>
                              <section>
                                 <id root="49437f03-385f-4af3-8ddb-1907d815cc7b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Human data</paragraph>
                                    <paragraph>Fourteen patients with active tuberculosis treated with multiple antituberculosis drugs including PRIFTIN became pregnant during clinical studies. Six delivered normal infants, four had first trimester spontaneous abortions (of these, one patient abused ethanol and another patient was HIV-infected), one had an elective abortion, and outcome was unknown in three patients. These data are, however, limited by the quality of reporting and confounded by comorbid medical conditions and multiple antituberculosis drug exposures.</paragraph>
                                    <paragraph>In the trial that compared the safety and effectiveness of PRIFTIN in combination with isoniazid to isoniazid alone for the treatment of latent tuberculosis infection, a total of 45 (2.5%) women in the PRIFTIN/isoniazid arm and 71 (4.1%) women in the isoniazid arm became pregnant. Among the 46 total pregnancies in the PRIFTIN/isoniazid arm, there were 31 live births, 6 elective abortions, 7 spontaneous abortions, and 2 unknown outcomes. Of the 31 live infants, 21 were reported healthy while in the other ten cases no further details were available. The rate of spontaneous abortion in the PRIFTIN/isoniazid arm (15%) and the rate of spontaneous abortion in the isoniazid arm (19%) did not represent an increase over the background rate of 15 to 20 percent reported in the general population. Further interpretation of these results is limited by the quality of adverse event reporting.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="c9cef1f8-8468-4d27-93f0-b2ff8507a66e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Animal data</paragraph>
                                    <paragraph>Animal studies in rats and rabbits revealed malformations and other adverse developmental outcomes in both species. Pregnant rats given oral rifapentine during organogenesis (gestational days 5 through 15) at 40 mg/kg/day (0.6 times the human dose of 600 mg based on body surface area comparisons) produced pups with cleft palates and mal-positioned aortic arches, delayed ossification, increased number of ribs, a decrease in litter size and mean litter weight, an increase in number of stillbirths, and an increase in mortality during lactation.</paragraph>
                                    <paragraph>When rifapentine was administered orally to mated female rats late in gestation, at 20 mg/kg/day (0.3 times the human dose based on body surface area), pup weights and gestational survival (live pups born/pups born) were reduced compared to controls. Increased resorptions and postimplantation loss, decreased mean fetal weights, increased numbers of stillborn pups, and slightly increased pup mortality during lactation were also noted. When pregnant rabbits received oral rifapentine at 10 mg/kg to 40 mg/kg (0.3 times to 1.3 times the human dose based on body surface area) during organogenesis (GD6 to GD18), major fetal malformations occurred including: ovarian agenesis, pes varus, arhinia, microphthalmia, and irregularities of the ossified facial tissues. At 40 mg/kg/day, there were increases in postimplantation loss and the incidence of stillborn pups.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="cb0ccbbe-d7ce-496a-98c8-f627439c05c2"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="20a9bf31-cf8c-4736-aaaa-e2011bfeedc2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of rifapentine or its metabolite in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Since PRIFTIN may produce a red-orange discoloration of body fluids, there is a potential for discoloration of breast milk. Monitor infants exposed to rifapentine through breast milk for signs of hepatotoxicity <content styleCode="italics">(see <linkHtml href="#CC2">Clinical Considerations</linkHtml>)</content>. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PRIFTIN and any potential adverse effects on the breastfed infant from PRIFTIN or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC2">
                           <id root="49216fe9-4e5f-4243-a11d-00fe1627189e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Monitor infants exposed to rifapentine through breast milk for signs of hepatotoxicity to include irritability, prolonged unexplained crying, yellowing of the eyes, loss of appetite, vomiting, and changes in color of the urine (darkening) or stool (lightening, pale or light brown).</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="3aae8915-3cc5-4776-887f-b6e53100949b"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="93240b09-744e-40d3-a616-5524cfd37d51"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Use of PRIFTIN may reduce the efficacy of hormonal contraceptives. Advise patients using hormonal contraceptives to use an alternative non-hormonal contraceptive method or add a barrier method of contraception during treatment with PRIFTIN <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="c79ac452-7e9c-4fa3-9d58-a1f6fd25d44d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 	Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of PRIFTIN in the treatment of active pulmonary tuberculosis have not been established in pediatric patients under the age of 12.</paragraph>
                        <paragraph>The safety and effectiveness of PRIFTIN in combination with isoniazid once-weekly regimen has been evaluated in pediatric patients (2 to 17 years of age) for the treatment of latent tuberculosis infection. In clinical studies, the safety profile in children was similar to that observed in adult patients <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>In a pharmacokinetic study conducted in 2 to 11-year-old pediatric patients with latent tuberculosis infection, PRIFTIN was administered once weekly based on weight (15 mg/kg to 30 mg/kg, up to a maximum of 900 mg). Exposures (AUC) in children 2 to 11 years old with latent tuberculosis infection were higher (average 31%) than those observed in adults receiving PRIFTIN 900 mg once weekly <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="345709a7-4361-40db-adef-faf748aed2ab"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 	Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies with PRIFTIN did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. In a pharmacokinetic study with PRIFTIN, no substantial differences in the pharmacokinetics of rifapentine and 25-desacetyl metabolite were observed in the elderly compared to younger adults <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="dd614986-7733-4b4e-aaac-8bf0e247ebde"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10	OVERDOSAGE</title>
               <text>
                  <paragraph>While there is no experience with the treatment of acute overdose with PRIFTIN, clinical experience with rifamycins suggests that gastric lavage to evacuate gastric contents (within a few hours of overdose), followed by instillation of an activated charcoal slurry into the stomach, may help adsorb any remaining drug from the gastrointestinal tract.</paragraph>
                  <paragraph>Rifapentine and 25-desacetyl rifapentine are 97.7% and 93.2% plasma protein bound, respectively. Rifapentine and related compounds excreted in urine account for only 17% of the administered dose, therefore, neither hemodialysis nor forced diuresis is expected to enhance the systemic elimination of unchanged rifapentine from the body of a patient with PRIFTIN overdose.</paragraph>
               </text>
               <effectiveTime value="20250521"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="a28ec808-58bd-4b80-9b1e-328f68e6c1a7"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11	DESCRIPTION</title>
               <text>
                  <paragraph>PRIFTIN (rifapentine) for oral administration contains 150 mg of the active ingredient rifapentine per tablet.</paragraph>
                  <paragraph>The 150 mg tablets also contain, as inactive ingredients: calcium stearate, disodium EDTA, FD&amp;C Blue No. 2 aluminum lake, hydroxypropyl cellulose, hypromellose USP, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, propylene glycol, sodium ascorbate, sodium lauryl sulfate, sodium starch glycolate, synthetic red iron oxide, and titanium dioxide.</paragraph>
                  <paragraph>Rifapentine is a rifamycin derivative antimicrobial and has a similar profile of microbiological activity to rifampicin. The molecular weight is 877.04.</paragraph>
                  <paragraph>The molecular formula is C<sub>47</sub>H<sub>64</sub>N<sub>4</sub>O<sub>12</sub>.</paragraph>
                  <paragraph>The chemical name for rifapentine is rifamycin, 3-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]- or 3-[N-(4-cyclopentyl - 1-piperazinyl)formimidoyl] rifamycin or 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-cyclopentyl-l-piperazinyl)-formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate. It has the following structure:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20250521"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3a64fb70-b85e-43d9-8bcd-7e893f568ae1-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="14bab106-05f1-4d67-9eb4-02d5de60e5e7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250521"/>
               <component>
                  <section ID="S12.1">
                     <id root="cecc2e8e-163e-40a4-8c64-5cbb78c4dd69"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="0c265306-3f98-482d-a814-08d19db0690d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics</title>
                     <text>
                        <paragraph>When oral doses of PRIFTIN were administered once daily or once every 72 hours to healthy volunteers for 10 days, single dose AUC <sub>(0ââ)</sub> of rifapentine was similar to its steady-state AUC<sub>ss (0â24h)</sub> or AUC<sub>ss (0â72h)</sub> values, suggesting no significant auto-induction effect on steady-state pharmacokinetics of rifapentine. Steady-state conditions were achieved by day 10 following daily administration of PRIFTIN 600 mg. No plasma accumulation of rifapentine and 25-desacetyl rifapentine (active metabolite) is expected after once weekly administration of PRIFTIN.</paragraph>
                        <paragraph>The pharmacokinetic parameters of rifapentine and 25-desacetyl rifapentine on day 10 following oral administration of 600 mg PRIFTIN every 72 hours to healthy volunteers are described in Table 5.</paragraph>
                        <table width="75%" ID="table5">
                           <caption>Table 5: Pharmacokinetics and Rifapentine and 25-Desacetyl Rifapentine in Healthy Volunteers</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" rowspan="2">Parameter</th>
                                 <th styleCode="Rrule Botrule">Rifapentine</th>
                                 <th styleCode="Rrule Botrule">25-desacetyl Rifapentine</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule" colspan="2" align="center">Mean Â± SD (n=12)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule">C<sub>max</sub> (Âµg/mL)</td>
                                 <td styleCode="Rrule">15.05 Â± 4.62</td>
                                 <td styleCode="Rrule">6.26 Â± 2.06</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">AUC <sub>(0â72h) (</sub>Âµgâh/mL)         </td>
                                 <td styleCode="Rrule">319.54 Â± 91.52</td>
                                 <td styleCode="Rrule">215.88 Â± 85.96</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">T<sub>1/2 </sub>(h)</td>
                                 <td styleCode="Rrule">13.19 Â± 1.38</td>
                                 <td styleCode="Rrule">13.35 Â± 2.67</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">T<sub>max</sub> (h)</td>
                                 <td styleCode="Rrule">4.83 Â± 1.80</td>
                                 <td styleCode="Rrule">11.25 Â± 2.73</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Cl/F (L/h)</td>
                                 <td styleCode="Rrule">2.03 Â± 0.60</td>
                                 <td styleCode="Rrule">--</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The pharmacokinetic parameters of rifapentine and 25-desacetyl rifapentine following single-dose oral administration of 900 mg PRIFTIN in combination with 900 mg isoniazid in fed conditions are described in Table 6.</paragraph>
                        <table width="75%" ID="table6">
                           <caption>Table 6: Mean Â± SD Pharmacokinetic Parameters of Rifapentine and 25-Desacetyl Rifapentine in Healthy Volunteers When PRIFTIN is Coadministered with Isoniazid Under Fed Conditions (N=16)</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule">Parameter</th>
                                 <th styleCode="Rrule">Rifapentine</th>
                                 <th styleCode="Rrule">25-desacetyl Rifapentine</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule">C<sub>max</sub> (Âµg/mL)</td>
                                 <td styleCode="Rrule">25.8 Â± 5.83</td>
                                 <td styleCode="Rrule">13.3 Â± 4.83</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">AUC (Âµgâh/mL)</td>
                                 <td styleCode="Rrule">817 Â± 128</td>
                                 <td styleCode="Rrule">601 Â± 187</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">T<sub>1/2</sub>(h)</td>
                                 <td styleCode="Rrule">16.6 Â± 5.02</td>
                                 <td styleCode="Rrule">17.5 Â± 7.42</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">T<sub>max</sub> (h)<footnote ID="t6f1">Median (MinâMax).</footnote>
                                 </td>
                                 <td styleCode="Rrule">8 (3â10)</td>
                                 <td styleCode="Rrule">24 (10â36)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Cl/F (L/h)</td>
                                 <td styleCode="Rrule">1.13 Â± 0.174</td>
                                 <td styleCode="Rrule">NA<footnote ID="t6f2">Not Applicable.</footnote>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="da02663e-777f-4de1-b066-ee0abe715cec"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The absolute bioavailability of PRIFTIN has not been determined. The relative bioavailability (with an oral solution as a reference) of PRIFTIN after a single 600 mg dose to healthy adult volunteers was 70%. The maximum concentrations were achieved from 5 hours to 6 hours after administration of the 600 mg PRIFTIN dose.</paragraph>
                              <paragraph>The administration of PRIFTIN with a high fat meal increased rifapentine C<sub>max</sub> and AUC by 40% to 50% over that observed when PRIFTIN was administered under fasting conditions.</paragraph>
                              <paragraph>The administration of PRIFTIN (900 mg single dose) and isoniazid (900 mg single dose) with a low fat, high carbohydrate breakfast, led to a 47% and 51% increase in rifapentine C<sub>max</sub> and AUC, respectively. In contrast, the ingestion of the same meal decreased isoniazid C<sub>max </sub>and AUC by 46% and of 23%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ea7d4478-58a2-4c01-840d-02140563d5c8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>In a population pharmacokinetic analysis in 351 tuberculosis patients who received 600 mg PRIFTIN in combination with isoniazid, pyrazinamide and ethambutol, the estimated apparent volume of distribution was 70.2 Â± 9.1 L. In healthy volunteers, rifapentine and 25-desacetyl rifapentine were 97.7% and 93.2% bound to plasma proteins, respectively. Rifapentine was mainly bound to albumin. Similar extent of protein binding was observed in healthy volunteers, asymptomatic HIV-infected subjects and hepatically impaired subjects.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2e91dee2-7f46-46d5-9990-0e6ce5bb62d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism/Excretion</content>
                              </paragraph>
                              <paragraph>Following a single 600 mg oral dose of radiolabeled rifapentine to healthy volunteers (n=4), 87% of the total <sup>14</sup>C-rifapentine was recovered in the urine (17%) and feces (70%). Greater than 80% of the total <sup>14</sup>C-rifapentine dose was excreted from the body within 7 days. Rifapentine was hydrolyzed by an esterase enzyme to form a microbiologically active 25-desacetyl rifapentine. Rifapentine and 25-desacetyl rifapentine accounted for 99% of the total radioactivity in plasma. Plasma AUC<sub>(0ââ)</sub> and C<sub>max</sub> values of the 25-desacetyl rifapentine metabolite were one-half and one-third those of the rifapentine, respectively. Based upon relative <content styleCode="italics">in vitro</content> activities and AUC<sub>(0â â)</sub> values, rifapentine and 25-desacetyl rifapentine potentially contributes 62% and 38% to the clinical activities against <content styleCode="italics">M. tuberculosis</content>, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="898ac7bf-9e02-4438-8338-7e8e62898a36"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                           <component>
                              <section>
                                 <id root="6c899851-b7b0-489a-af9b-ff68dc6f5944"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Gender:</content> In a population pharmacokinetics analysis of sparse blood samples obtained from 351 tuberculosis patients who received 600 mg PRIFTIN in combination with isoniazid, pyrazinamide and ethambutol, the estimated apparent oral clearance of PRIFTIN for males and females was 2.51 Â± 0.14 L/h and 1.69 Â± 0.41 L/h, respectively. The clinical significance of the difference in the estimated apparent oral clearance is not known.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="93ba0b8c-404d-4d3c-a635-e8dde4f21006"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Elderly:</content> Following oral administration of a single 600 mg dose of PRIFTIN to elderly (65 years and older) male healthy volunteers (n=14), the pharmacokinetics of rifapentine and 25-desacetyl metabolite were similar to that observed for young (18 to 45 years) healthy male volunteers (n=20).</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="c566319b-921b-4fc6-90d1-6232f4194455"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Pediatric: </content>In a pharmacokinetic study in pediatric patients (age 2 to 12 years), a single oral dose of 150 mg PRIFTIN was administered to those weighing less than 30 kg (n=11) and a single oral dose of 300 mg was administered to those weighing greater than 30 kg (n=12). The mean estimates of AUC and C<sub>max</sub> were approximately 30% to 50% lower in these pediatric patients than those observed in healthy adults administered single oral doses of 600 mg and 900 mg.</paragraph>
                                    <paragraph>A study compared the pharmacokinetics of rifapentine in pediatric patients (age 2 years to 11 years) with latent tuberculosis infection (n=80) receiving PRIFTIN once weekly based on weight (15 mg/kg to 30 mg/kg, up to a maximum of 900 mg, see <linkHtml href="#table1">Table 1</linkHtml>) to that of adults (n=77) receiving PRIFTIN 900 mg once weekly. Children who could not swallow whole tablets were administered crushed tablets mixed in soft food. Overall, the geometric mean AUC of rifapentine in this age group was 31% higher compared to adult patients receiving 900 mg PRIFTIN once weekly (720 versus 551 mcgâh/mL). The geometric mean AUC of rifapentine was 60% higher in children administered whole tablets (884 versus 551 mcgâh/mL) and 19% higher in children administered crushed tablets (656 versus 551 mcgâh/mL), as compared to exposures in adults. Pediatric patients administered crushed PRIFTIN tablets had 26% lower rifapentine exposures compared to those pediatric patients who were given whole tablets.</paragraph>
                                    <paragraph>Population pharmacokinetic analysis showed that rifapentine clearance adjusted to body weight decreased with increasing age of pediatric patients (2 to 18 years).</paragraph>
                                    <paragraph>In another pharmacokinetics study of PRIFTIN in healthy adolescents (age 12 to 15 years), 600 mg PRIFTIN was administered to those weighing â¥45 kg (n=10) and 450 mg was administered to those weighing less than 45 kg (n=2). The pharmacokinetics of rifapentine was similar to those observed in healthy adults.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9d20971a-930b-4305-ae49-f7a4dd21188d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Renal Impaired Patients:</content> The pharmacokinetics of rifapentine has not been evaluated in renal impaired patients. Although only about 17% of an administered dose is excreted via the kidneys, the clinical significance of impaired renal function on the disposition of rifapentine and its 25-desacetyl metabolite is not known.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="8050d622-65c3-4563-9e01-8204b34c428b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Hepatic Impaired Patients:</content> Following oral administration of a single 600 mg dose of PRIFTIN to mild to severe hepatic impaired patients (n=15), the pharmacokinetics of rifapentine and 25-desacetyl metabolite were similar in patients with various degrees of hepatic impairment and to that observed in another study for healthy volunteers (n=12).</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="350ff0c4-2a52-4669-bb32-23378120f8e0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Asymptomatic HIV-Infected Volunteers:</content> Following oral administration of a single 600 mg dose of PRIFTIN to asymptomatic HIV-infected volunteers (n=15) under fasting conditions, mean C<sub>max</sub> and AUC<sub>(0ââ)</sub> of rifapentine were lower (20%â32%) than that observed in other studies in healthy volunteers (n=55). In a cross-study comparison, mean C<sub>max</sub> and AUC values of the 25-desacetyl rifapentine, when compared to healthy volunteers were higher (6%â21%) in one study (n=20), but lower (15%â16%) in a different study (n=40). The clinical significance of this observation is not known. Food (850 total calories: 33 g protein, 55 g fat, and 58 g carbohydrate) increases the mean AUC and C<sub>max</sub> of rifapentine observed under fasting conditions in asymptomatic HIV-infected volunteers by about 51% and 53%, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="80f043c6-cc81-46ec-b39f-33a7e01844e6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug-Drug Interactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                           <component>
                              <section>
                                 <id root="8e3765ab-44db-428f-a6d0-c7b073417837"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Isoniazid:</content> Coadministration of PRIFTIN (900 mg single dose) and isoniazid (900 mg single dose), in fasted condition, did not result in any significant change in the exposure of rifapentine and isoniazid compared to when administered alone in fasted condition.</paragraph>
                                    <paragraph>Rifapentine is an inducer of cytochrome P450 3A4 and 2C8/9. Therefore, it may increase the metabolism and decrease the activity of other coadministered drugs that are metabolized by these enzymes. Dosage adjustments of the coadministered drugs may be necessary if they are given concurrently with PRIFTIN <content styleCode="italics">[see <linkHtml href="#S7.4">Drug Interactions (7.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d448f9ac-9340-45cc-806c-c42b465f4161"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Indinavir:</content> In a study in which 600 mg PRIFTIN was administered twice weekly for 14 days followed by PRIFTIN twice weekly plus 800 mg indinavir 3 times a day for an additional 14 days, indinavir C<sub>max </sub>decreased by 55% while AUC reduced by 70%. Clearance of indinavir increased by 3-fold in the presence of PRIFTIN while half-life did not change. But when indinavir was administered for 14 days followed by coadministration with PRIFTIN for an additional 14 days, indinavir did not affect the pharmacokinetics of rifapentine <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="870b016f-956c-4d0f-a7ee-6a068aff7e54"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Fixed-dose combination of efavirenz, emtricitabine and tenofovir: </content>Once-weekly coadministration of 900 mg PRIFTIN with the antiretroviral fixed-dose combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in HIV-infected patients did not result in any substantial change in steady state exposures of efavirenz, emtricitabine, and tenofovir (Table 7). A 15% decrease in efavirenz C<sub>min </sub>and AUC and a 13% decrease in tenofovir C<sub>min</sub> were observed with repeated weekly doses of PRIFTIN (Table 7). No clinically significant change in CD4 cell counts or viral loads were noted.</paragraph>
                                    <table width="85%" ID="table7">
                                       <caption>Table 7: Treatment Ratio Estimates (with versus without repeated once-weekly PRIFTIN 900 mg) with 90% Confidence Intervals for Efavirenz, Emtricitabine and Tenofovir Pharmacokinetic Parameters</caption>
                                       <col width="10%" align="center" valign="top"/>
                                       <col width="30%" align="center" valign="top"/>
                                       <col width="30%" align="center" valign="top"/>
                                       <col width="30%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule">Efavirenz<br/>Point Estimates<br/>(90% CI)</th>
                                             <th styleCode="Rrule">Emtricitabine<br/>Point Estimates<br/>(90% CI)</th>
                                             <th styleCode="Rrule">Tenofovir<br/>Point Estimates<br/>(90% CI)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">C<sub>max</sub>
                                             </td>
                                             <td styleCode="Rrule">0.92 (0.82â1.03)</td>
                                             <td styleCode="Rrule">0.95 (0.81â1.10)</td>
                                             <td styleCode="Rrule">1.00 (0.82â1.22)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">C<sub>min</sub>
                                             </td>
                                             <td styleCode="Rrule">0.85 (0.79â0.93)</td>
                                             <td styleCode="Rrule">0.97 (0.90â1.05)</td>
                                             <td styleCode="Rrule">0.87(0.73â1.05)</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">AUC<sub>0â24</sub>
                                             </td>
                                             <td styleCode="Rrule">0.86 (0.79â0.93)</td>
                                             <td styleCode="Rrule">0.93 (0.89â0.98)</td>
                                             <td styleCode="Rrule">0.91(0.85â0.98)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250521"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="9e962b19-b3df-442b-aa47-e12f413f76f4"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4	Microbiology </title>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="e5058612-f240-4ca6-b69a-666f78313f53"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Rifapentine, a cyclopentyl rifamycin, inhibits DNA-dependent RNA polymerase in susceptible strains of <content styleCode="italics">Mycobacterium tuberculosis</content> but does not affect mammalian cells at concentrations that are active against these bacteria. At therapeutic levels, rifapentine inhibits RNA transcription by preventing the initiation of RNA chain formation. It forms a stable complex with bacterial DNA-dependent RNA polymerase, leading to repression of RNA synthesis and cell death. Rifapentine and its 25-desacetyl metabolite accumulate in human monocyte-derived macrophages and are bactericidal to both intracellular and extracellular <content styleCode="italics">M. tuberculosis </content>bacilli.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="47e5e209-ad90-484c-8faa-ea7e58f7e5f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Resistance </content>
                              </paragraph>
                              <paragraph>The mechanism of resistance to rifapentine appears to be similar to that of rifampin. Bacterial resistance to rifapentine is caused by an alteration in the target site, the beta subunit of the DNA-dependent RNA polymerase, caused by a one-step mutation in the rpoÎ² gene. The incidence of rifapentine resistant mutants in an otherwise susceptible population of <content styleCode="italics">M. tuberculosis </content>strains is approximately one in 10<sup>7</sup> to 10<sup>8</sup> bacilli. Rifapentine resistance appears to be associated with monotherapy. Therefore, rifapentine should always be used in combination with other antituberculosis drugs.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="05cb5495-c23a-4139-854b-c9018ed6e7de"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross Resistance</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">M. tuberculosis </content>organisms resistant to other rifamycins are likely to be resistant to rifapentine. A high level of cross-resistance between rifamycin and rifapentine has been demonstrated with <content styleCode="italics">M. tuberculosis </content>strains. Cross-resistance between rifapentine and non-rifamycin antimycobacterial agents has not been identified in clinical isolates.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6355c40b-7883-4a29-85e8-1f168ddeff2e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Susceptibility Testing</content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="495644a0-68db-441e-9b1b-17a4f50846c6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250521"/>
               <component>
                  <section ID="S13.1">
                     <id root="0aa6ab29-d0ba-4611-9a9d-8e2b871e84f4"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Hepatocellular carcinomas were increased in male NMRI mice (Harlan Winklemann) which were treated orally with rifapentine for two years at or above doses of 5 mg/kg/day (0.04 times the recommended human dose based on body surface area conversions). In a two year rat study, there was an increase in nasal cavity adenomas in Wistar rats treated orally with rifapentine at 40 mg/kg/day (0.6 times human dose based on body surface area conversions).</paragraph>
                        <paragraph>Rifapentine was negative in the following genotoxicity tests: <content styleCode="italics">in vitro</content> gene mutation assay in bacteria (Ames test); <content styleCode="italics">in vitro</content> point mutation test in <content styleCode="italics">Aspergillus nidulans</content>; <content styleCode="italics">in vitro</content> gene conversion assay in <content styleCode="italics">Saccharomyces cerevisiae</content>; host-mediated (mouse) gene conversion assay with <content styleCode="italics">Saccharomyces cerevisiae</content>; <content styleCode="italics">in vitro</content> Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyltransferase (CHO/HGPRT) forward mutation assay; <content styleCode="italics">in vitro</content> chromosomal aberration assay utilizing rat lymphocytes; and <content styleCode="italics">in vivo</content> mouse bone marrow micronucleus assay.</paragraph>
                        <paragraph>The 25-desacetyl metabolite of rifapentine was positive in the <content styleCode="italics">in vitro</content> mammalian chromosome aberration test in V79 Chinese hamster cells, but was negative in the <content styleCode="italics">in vitro</content> gene mutation assay in bacteria (Ames test), the <content styleCode="italics">in vitro</content> Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyltransferase (CHO/HGPRT) forward mutation assay, and the <content styleCode="italics">in vivo</content> mouse bone marrow micronucleus assay. Fertility and reproductive performance were not affected by oral administration of rifapentine to male and female rats at doses of up to 20 mg/kg/day (one-third of the human dose based on body surface area conversions).</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="3ce8455b-2ae5-4213-8f29-d563d046bcd3"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <effectiveTime value="20250521"/>
               <component>
                  <section ID="S14.1">
                     <id root="2b569909-92d4-4f36-86a0-69bf273c423e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Active Pulmonary Tuberculosis</title>
                     <text>
                        <paragraph>PRIFTIN was studied in two randomized, open-label controlled clinical trials in the treatment of active pulmonary tuberculosis.</paragraph>
                        <paragraph>The first trial was an open-label, prospective, parallel group, active-controlled trial in HIV-negative patients with active pulmonary tuberculosis. The population mostly comprised Black (approximately 60%) or multiracial (approximately 31%) patients. Treatment groups were comparable for age and sex and consisted primarily of male subjects with a mean age of 37 Â± 11 years. In the initial 2-month phase of treatment, 361 patients received PRIFTIN 600 mg twice a week in combination with daily isoniazid, pyrazinamide, and ethambutol and 361 subjects received rifampin 600 mg in combination with isoniazid, pyrazinamide and ethambutol all administered daily. The doses of the companion drugs were the same in both treatment groups during the initial phase: isoniazid 300 mg, pyrazinamide 2000 mg, and ethambutol 1200 mg. For patients weighing less than 50 kg, the doses of rifampin (450 mg), pyrazinamide (1500 mg) and ethambutol (800 mg) were reduced. Ethambutol was discontinued when isoniazid and rifampin susceptibility testing results were confirmed. During the 4-month continuation phase, 317 patients in the PRIFTIN group continued to receive PRIFTIN 600 mg dosed once weekly with isoniazid 300 mg and 304 patients in the rifampin group received twice weekly rifampin and isoniazid 900 mg. For patients weighing less than 50 kg, the doses of rifampin (450 mg) and isoniazid (600 mg) were reduced. Both treatment groups received pyridoxine (Vitamin B6) over the 6-month treatment period. Treatment was directly observed. 65/361 (18%) of patients in the PRIFTIN group and 34/361 (9%) in the rifampin group received overdoses of one or more of the administered study medications during the initial or continuation phase of treatment. Seven of these patients had adverse reactions reported with the overdose (5 in the PRIFTIN group and 2 in the rifampin group).</paragraph>
                        <paragraph>Table 8 below contains assessments of sputum conversion at end of treatment (6 months) and relapse rates at the end of follow-up (24 months).</paragraph>
                        <table width="75%" ID="table8">
                           <caption>Table 8: Clinical Outcome in HIV Negative Patients with Active Pulmonary Tuberculosis (Trial 1)</caption>
                           <col width="40%" align="center" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" align="center">PRIFTIN Combination Treatment % and (n/N<footnote ID="t8f1">All data for patients with confirmed susceptible <content styleCode="italics">M. tuberculosis</content> (PRIFTIN combination treatment, N=286; rifampin combination treatment, N=283).</footnote>)</th>
                                 <th styleCode="Rrule" align="center">Rifampin Combination Treatment % and (n/N<footnoteRef IDREF="t8f1"/>)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3" align="left">
                                    <content styleCode="bold">Status at End of 6 months of Treatment</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Â Â Converted</td>
                                 <td styleCode="Rrule">87% (248/286)</td>
                                 <td styleCode="Rrule">80% (226/283)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Â Â Not Converted</td>
                                 <td styleCode="Rrule">1% (4/286)</td>
                                 <td styleCode="Rrule">3% (8/283)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Â Â Lost to Follow-up</td>
                                 <td styleCode="Rrule">12% (34/286)</td>
                                 <td styleCode="Rrule">17% (49/283)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3" align="left">
                                    <content styleCode="bold">Status Through 24 Month Follow-up</content>
                                    <footnote ID="t8f2">Twenty-two (22) deaths occurred during the study; 11 in each treatment group.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Â Â Relapsed</td>
                                 <td styleCode="Rrule">12% (29/248)</td>
                                 <td styleCode="Rrule">7% (15/226)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Â Â Sputum Negative</td>
                                 <td styleCode="Rrule">57% (142/248)</td>
                                 <td styleCode="Rrule">64% (145/226)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Â Â Lost to Follow-up</td>
                                 <td styleCode="Rrule">31% (77/248)</td>
                                 <td styleCode="Rrule">29% (66/226)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Risk of relapse was greater in the group treated with the PRIFTIN combination. Higher relapse rates were associated with a lower rate of compliance as well as a failure to convert sputum cultures at the end of the initial 2-month treatment phase. Relapse rates were also higher for males in both regimens. Relapse in the PRIFTIN group was not associated with development of monoresistance to rifampin.</paragraph>
                        <paragraph>The second trial was randomized, open-label performed in 1075 HIV-negative and HIV-positive patients with active pulmonary tuberculosis. Patients with culture-positive, drug-susceptible pulmonary tuberculosis who had completed the initial 2-month phase of treatment with 4 drugs (rifampin, isoniazid, pyrazinamide, and either ethambutol or streptomycin) under direct observation were randomly assigned to receive either PRIFTIN 600 mg and isoniazid 15 mg/kg (max 900 mg) once weekly or rifampin 10 mg/kg (max 600 mg) and isoniazid 15 mg/kg (max 900 mg) twice weekly for the 4 month continuation phase. Study drugs were given under direct observation therapy in both groups.</paragraph>
                        <paragraph>In the PRIFTIN group, 502 HIV-negative and 36 HIV-positive patients were randomized and in the rifampin group 502 HIV-negative and 35 HIV-positive patients were randomized to treatment. Enrollment of HIV-infected patients was stopped when 4 of 36 patients in the PRIFTIN combination group relapsed with isolates that were rifampin resistant.</paragraph>
                        <paragraph>Table 9 below contains assessments of sputum conversion at the end of treatment (6 months total: 2 months of initial and 4 months of randomized continuation treatment) and relapse rates at the end of follow-up (24 months) in all HIV-negative patients randomized to treatment. Positive culture was based on either one sputum sample with &gt;10 colonies on solid media OR at least 2 positive sputum samples on liquid or solid media. However, only one sputum sample was collected at each visit in a majority of patients.</paragraph>
                        <table width="75%" ID="table9">
                           <caption>Table 9: Clinical Outcome in HIV Negative Patients with Active Pulmonary Tuberculosis (Trial 2)</caption>
                           <col width="40%" align="left" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">PRIFTIN Combination Treatment % (n/N)</th>
                                 <th styleCode="Rrule">Rifampin Combination Treatment % (n/N)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Status at End of 4 Months Continuation Phase</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Treatment Response<footnote ID="t9f1">Treatment response was defined as subjects who had two negative sputum cultures after 16 doses of rifampin and isoniazid or after 8 doses of PRIFTIN and isoniazid, and remained sputum negative through the end of continuation phase therapy.</footnote>
                                 </td>
                                 <td styleCode="Rrule">93.8% (471/502)</td>
                                 <td styleCode="Rrule">91% (457/502)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Not Converted</td>
                                 <td styleCode="Rrule">1% (5/502)</td>
                                 <td styleCode="Rrule">1.2% (6/502)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Did Not Complete Treatment<footnote ID="t9f2">Due to drug toxic effects, non-adherence, withdrawal of consent, receipt of non-study regimen, other.</footnote>
                                 </td>
                                 <td styleCode="Rrule">4.2% (21/502)</td>
                                 <td styleCode="Rrule">7% (35/502)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Deaths</td>
                                 <td styleCode="Rrule">1% (5/502)</td>
                                 <td styleCode="Rrule">0.8% (4/502)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Status Through 24 Month Follow-up:</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Relapsed</td>
                                 <td styleCode="Rrule">8.7% (41/471)</td>
                                 <td styleCode="Rrule">4.8% (22/457)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Sputum Negative</td>
                                 <td styleCode="Rrule">79.4% (374/471)</td>
                                 <td styleCode="Rrule">80.1% (366/457)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Lost to Follow-up</td>
                                 <td styleCode="Rrule">7.9% (37/471)</td>
                                 <td styleCode="Rrule">9.8% (45/457)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Deaths</td>
                                 <td styleCode="Rrule">4% (19/471)</td>
                                 <td styleCode="Rrule">5.3% (24/457)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In HIV-negative patients, higher relapse rates were seen in patients with a positive sputum culture at 2 months (i.e., at the time of study randomization), cavitation on chest x-ray, and bilateral pulmonary involvement.</paragraph>
                        <paragraph>Sixty-one HIV-positive patients were assessed for relapse. The rates of relapse were 16.7% (5/30) in the PRIFTIN group and 9.7% (3/31) in the rifampin group. In HIV-positive patients, 4 of the 5 relapses in the PRIFTIN combination group involved <content styleCode="italics">M. tuberculosis</content> strains with rifampin monoresistance. No relapse strain in the twice weekly rifampin/isoniazid group acquired drug resistance.</paragraph>
                        <paragraph>The death rate among all study participants did not differ between the two treatment groups.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="590661dc-dc35-4819-af2f-26d105e1238b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Latent Tuberculosis Infection</title>
                     <text>
                        <paragraph>A multicenter, prospective, open-label, randomized, active-controlled trial compared the effectiveness of 12 weekly doses of PRIFTIN in combination with isoniazid (3RPT/INH arm) administered by directly observed therapy to 9 months of self-administered daily isoniazid (9INH arm). The trial enrolled patients two years of age or older with positive tuberculin skin test and at high risk for progression to tuberculosis disease. Enrolled patients included those having close contact with a patient with active tuberculosis disease, recent (within two years) conversion to a positive tuberculin skin test, HIV-infection, or fibrosis on chest radiograph. PRIFTIN was dosed by weight, for a maximum of 900 mg weekly. Isoniazid mg/kg dose was determined by age, for a maximum of 900 mg weekly in the 3RPT/INH arm and 300 mg daily in the 9INH arm <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>The outcome measure was the development of active tuberculosis disease, defined as culture-confirmed tuberculosis in adults and culture-confirmed or clinical tuberculosis in children less than 18 years of age, at 33 months after trial enrollment. Patients who were found after enrollment to be ineligible because they had active tuberculosis disease, were contacts of a source case with culture-negative or drug-resistant tuberculosis disease cases or no information regarding susceptibility of <content styleCode="italics">M. tuberculosis</content>, and young children lacking a positive TST on initial and repeat testing were excluded from the analysis.</paragraph>
                        <paragraph>Active tuberculosis disease developed in 5 of 3074 randomized patients in the 3RPT/INH group (0.16%) versus 10 of 3074 patients in 9INH group (0.32%), for a difference in cumulative rates of 0.17%, 95% CI (-0.43, 0.09) (Table 10).</paragraph>
                        <table width="85%" ID="table10">
                           <caption>Table 10: Outcomes in Randomized Patients at 33 Months Post Enrollment<footnote ID="t10f1">Similar results were observed when all enrolled patients were included in the analysis.</footnote>
                           </caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Outcome</th>
                                 <th styleCode="Rrule">3RPT/INH (n=3074)</th>
                                 <th styleCode="Rrule">9INH (n=3074)</th>
                                 <th styleCode="Rrule">Difference<footnote ID="t10f2">Rate in the 3RPT/INH group minus the rate in the 9INH group.</footnote>, 95% CI</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Tuberculosis n (%)</td>
                                 <td styleCode="Rrule">5 (0.16)</td>
                                 <td styleCode="Rrule">10 (0.32)</td>
                                 <td styleCode="Rrule">-0.16 (-0.42, 0.01)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Cumulative TB Rate (%)</td>
                                 <td styleCode="Rrule">0.17</td>
                                 <td styleCode="Rrule">0.35</td>
                                 <td styleCode="Rrule">-0.17 (-0.43, 0.09)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Deaths</td>
                                 <td styleCode="Rrule">22 (0.72)</td>
                                 <td styleCode="Rrule">35 (1.14)</td>
                                 <td styleCode="Rrule">-0.42 (-0.91, 0.06)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Lost to Follow-Up</td>
                                 <td styleCode="Rrule">320 (10.41)</td>
                                 <td styleCode="Rrule">357 (11.61)</td>
                                 <td styleCode="Rrule">-1.20 (-2.77, -0.36)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The proportion of patients completing treatment was 81.2% in the 3RPT/INH group and 68.3% in the 9INH group for a difference (3RPT/INH-9INH) of 12.8% 95% CI (10.7, 15.0).</paragraph>
                        <paragraph>In the 9INH treatment group, two of the thirteen culture-confirmed cases were found to be isoniazid-monoresistant. In the 3RPT/INH treatment group, one of the seven cases was rifampin-resistant, isoniazid-susceptible <content styleCode="italics">M. bovis</content> infection.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                     <component>
                        <section>
                           <id root="7d1fba3b-14c1-4213-a7a5-a17f5dcfba42"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric substudy</content>
                              </paragraph>
                              <paragraph>Enrollment of children was extended after the overall target number of patients was attained in the main study. Data from both the main study and the extension were pooled resulting in an eligible population for analysis of 375 children in the 3RPT/INH arm and 367 in the 9INH arm.</paragraph>
                              <paragraph>One child in the 9INH group developed tuberculosis (1/367, cumulative rate 0.32%) versus zero tuberculosis cases in the 3RPT/INH group (0/375) at 33 months post enrollment. The proportion of patients completing treatment in the 3RPT/INH and the 9INH groups was 87.5% and 79.6% respectively for a difference of 7.9%, 95% CI (2.5, 13.2).</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="008137ca-ffd2-410f-a3c4-d52a4780c69e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">HIV substudy</content>
                              </paragraph>
                              <paragraph>Enrollment of HIV-positive patients was extended after the overall target number of patients was attained in the main study. Data from both the main study and the extension were pooled resulting in an eligible population for analysis of 206 patients in the 3RPT/INH group and 193 in the 9INH group. Tuberculosis disease developed in 2/206 patients in the 3RPT/INH group (cumulative rate, 1.01%) and in 6/193 patients in the 9INH group (cumulative rate, 3.45%). The proportion of patients completing treatment in the 3RPT/INH and 9INH groups was 88.8% and 63.7%, respectively for a difference of 25.1%, 95% CI (16.8, 32.9).</paragraph>
                           </text>
                           <effectiveTime value="20250521"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="9b7611d3-2d8d-4a3a-8a4b-9fcbe6d38252"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250521"/>
               <component>
                  <section>
                     <id root="3fc50b74-04ad-4bca-9f3a-33e6bdd5fa21"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>PRIFTIN is supplied as 150 mg round normal convex dark-pink film-coated tablets debossed "F" on one side of tablet packaged in aluminum formable foil blister strips. </paragraph>
                        <paragraph>Carton of 24 tablets (3 strips of 8 tablets) NDC 0088-2102-24</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e1cd734a-f101-4011-b479-06bb398a3653"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <paragraph>Store at 25Â°C (77Â°F); excursions permitted 15â30Â°C (59â86Â°F) (see USP Controlled Room Temperature). Protect from excessive heat and humidity.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="6bc2ed6f-3107-4bda-a7fd-e8618afa29f4"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patient to read FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20250521"/>
               <component>
                  <section>
                     <id root="8ed9bb9f-76cf-4864-aa65-a90fd9854b0d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Treatment Adherence</content>
                        </paragraph>
                        <paragraph>Emphasize the importance of compliance with the full course of therapy, and the importance of not missing any doses of PRIFTIN or companion medications in the treatment of active pulmonary tuberculosis or the treatment of latent tuberculosis infection.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3511d843-db35-4b32-9f94-fa34363989d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that PRIFTIN may cause hypersensitivity reactions. Signs and symptoms of this reaction may include a flu-like illness, hypotension, urticaria, angioedema, bronchospasm, conjunctivitis, thrombocytopenia or neutropenia. Anaphylaxis may also occur <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Inform patients of signs and symptoms of hypersensitivity reactions and advise them to stop the medication and contact their healthcare provider if they experience any of these symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="662f4061-e3d4-4cdf-921d-25f073408afc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Severe Cutaneous Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking PRIFTIN immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="349d7c2a-63ac-4c80-aeb4-705c2d679bd4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatitis</content>
                        </paragraph>
                        <paragraph>Instruct patients to stop the medication and notify their physician promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="895bc098-7398-4b9d-ab3d-226bb72230df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Rifapentine may increase the metabolism and decrease the activity of other drugs that are metabolized by the P450 3A4 and 2C8/9 pathways. Dosage adjustments of the coadministered drugs may be necessary. Advise patients to discuss with their physician any other medications they are taking before starting treatment with PRIFTIN <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1</linkHtml>, <linkHtml href="#S7.4">7.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>Concomitant use of PRIFTIN with protease inhibitors or reverse transcriptase inhibitors may cause a significant decrease in plasma concentrations and loss of therapeutic effect of the protease inhibitor or reverse transcriptase inhibitor <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S7.4">Drug Interactions (7.4)</linkHtml>]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3dbcfe41-91ae-44fb-9696-6d7c9c75fdf7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Discoloration of Body Fluids</content>
                        </paragraph>
                        <paragraph>Inform the patient that PRIFTIN produces a red-orange discoloration of the urine, sweat, sputum, tears, and breast milk. Contact lenses or dentures may be permanently stained <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="cfdb1989-7e8e-4d96-9f99-3d25b26e85dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration with Food</content>
                        </paragraph>
                        <paragraph>Advise patients to take PRIFTIN with food.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a19cdf83-132e-47af-ad18-df354905f840"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Monitor infants exposed to rifapentine through breast milk for signs of hepatotoxicity to include irritability, prolonged unexplained crying, yellowing of the eyes, loss of appetite, vomiting, and changes in color of the urine (darkening) or stool (lightening, pale or light brown) <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c964b96a-ca5b-45d6-839b-62b6c1bb864c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Advise patients that use of PRIFTIN may reduce the efficacy of hormonal contraceptives. Advise patients using hormonal contraceptives to use an alternative non-hormonal contraceptive method or add a barrier method of contraception during treatment <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>, and <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250521"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3add23b4-d63d-4f19-99fa-5495b97cad24"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>sanofi-aventis U.S. LLC<br/>Morristown, NJ 07960<br/>A SANOFI COMPANY<br/>Â©2025 sanofi-aventis U.S. LLC</paragraph>
               </text>
               <effectiveTime value="20250521"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ada96c2f-6da8-4f13-b91a-042b2f664bb3"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="middle"/>
                     <col width="30%" align="left" valign="middle"/>
                     <col width="5%" align="left" valign="middle"/>
                     <col width="25%" align="left" valign="middle"/>
                     <col width="10%" align="left" valign="middle"/>
                     <col width="27%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" colspan="6" align="center">Medication Guide<br/>PRIFTIN (prif - tin)<br/>(rifapentine)<br/>Tablets</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="6">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                        </tr>
                        <tr>
                           <td align="left" colspan="6">Revised: May 2025</td>
                        </tr>
                        <tr>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">Read this Medication Guide before you start taking PRIFTIN and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <paragraph ID="What_is">
                                 <content styleCode="bold">What is the most important information I should know about PRIFTIN?</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">PRIFTIN may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Liver problems.</content> PRIFTIN may cause serious liver problems. Your doctor may do a blood test to check your liver function before and while you take PRIFTIN. Stop taking PRIFTIN and call your doctor right away if you have any of the following signs and symptoms of liver problems:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>nausea</item>
                                 <item>stomach pain</item>
                                 <item>tiredness, yellowing skin or whites of your eyes</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>vomiting</item>
                                 <item>loss of appetite</item>
                                 <item>dark urine</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Allergic reactions and flu-like symptoms.</content> Allergic reactions and flu-like symptoms have happened in some people taking PRIFTIN. Signs and symptoms of an allergic reaction may include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>low blood pressure (hypotension) </item>
                                 <item>hives</item>
                                 <item>cough with wheezing</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>difficulty breathing</item>
                                 <item>red eyes (conjunctivitis)</item>
                                 <item>lower blood platelet levels</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="5" styleCode="Rrule">Signs and symptoms of a flu-like reaction may include:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>weakness </item>
                                 <item>nausea and vomiting</item>
                                 <item>chills</item>
                                 <item>itching</item>
                                 <item>shortness of breath</item>
                                 <item>fainting</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>tiredness</item>
                                 <item>headache</item>
                                 <item>aches</item>
                                 <item>sweats</item>
                                 <item>chest pain</item>
                                 <item>fast heartbeat </item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>muscle pain</item>
                                 <item>fever</item>
                                 <item>rash</item>
                                 <item>dizziness</item>
                                 <item>cough</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Severe skin reactions.</content> Serious skin reactions such as Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome have happened in some people taking PRIFTIN.<br/>Stop taking PRIFTIN right away and call your doctor or get emergency help if you have any of the following symptoms:</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>rash</item>
                                 <item>red and painful skin</item>
                              </list>
                           </td>
                           <td colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>peeling or bleeding skin</item>
                                 <item>sores or blisters on the inside of your mouth or lips</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>swollen face, lips, mouth tongue or throat</item>
                                 <item>flu-like symptoms</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">What is PRIFTIN?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">PRIFTIN is a prescription medicine used with other anti-tuberculosis (TB) medicines to:<list listType="unordered" styleCode="disc">
                                 <item>treat active tuberculosis disease of the lung in people age 12 years and older.</item>
                                 <item>prevent progression of inactive (latent) tuberculosis infection to active tuberculosis disease in people age 2 years and older. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">PRIFTIN should not be used: 								<list listType="unordered" styleCode="disc">
                                 <item>alone to treat people with active or latent TB</item>
                                 <item>in people with active TB who had taken the medicines rifampin or isoniazid in the past and did not respond (resistant)</item>
                                 <item>in people who had been exposed to patients with TB that cannot be treated with isoniazid or rifampin</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">PRIFTIN is safe and effective in children older than 2 years of age who have inactive (latent TB), but it is not known if PRIFTIN is safe and effective for use in the treatment of active TB in children under 12 years of age.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">Who should not take PRIFTIN?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> take PRIFTIN if you are allergic to a group of medicines called rifamycins. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">What should I tell my doctor before taking PRIFTIN?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">Before taking PRIFTIN, tell your doctor about all of your medical conditions, including if you: </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have active TB disease.</item>
                                 <item>know that you have TB that is resistant to treatment with some medicines.</item>
                                 <item>have HIV infection or taking medicines to treat HIV infection.</item>
                                 <item>have liver problems.</item>
                                 <item>have a condition called porphyria.</item>
                                 <item>are pregnant or planning to become pregnant. It is not known if PRIFTIN will harm your unborn baby. </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if PRIFTIN passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking PRIFTIN.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Using PRIFTIN with other medicines may affect each other causing serious side effects. PRIFTIN may affect the way other medicines work, and other medicines may affect how PRIFTIN works. Especially tell your doctor if you take medicines to treat HIV infection or oral contraceptives. </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Ask your doctor or pharmacist for a list of these medicines if you are not sure.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">How should I take PRIFTIN? </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take PRIFTIN exactly as your doctor tells you to take it.<br/>
                                    <content styleCode="bold">It is important to take all of your PRIFTIN and your other TB medicines. Do not skip doses.</content> Skipping doses may cause PRIFTIN to not work as well and may increase the chance that your TB will not be treatable by PRIFTIN or other medicines.</item>
                                 <item>Take PRIFTIN with food.<br/>If you cannot swallow PRIFTIN tablets whole, they can be crushed and mixed with small amount of semisolid food. Be sure to take all of the semisolid food with PRIFTIN in it right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">What are possible side effects of PRIFTIN?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">PRIFTIN may cause serious side effects, including: </content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">see "<linkHtml href="#What_is">What is the most important information I should know about PRIFTIN?</linkHtml>"</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">relapse of your TB symptoms.</content> Active TB disease may return after improvement (relapse) in some people, especially people who do not take PRIFTIN exactly as their doctor tells them to. It is important that you take PRIFTIN exactly as your doctor tells you to. Your doctor should check you for worsening signs and symptoms of your TB while you take PRIFTIN.</item>
                                 <item>
                                    <content styleCode="bold">change in the normal color of your skin, mouth and body fluids.</content> PRIFTIN may cause your skin, teeth, tongue, urine, feces, saliva, sputum, tears, sweat, and breast milk to turn a red-orange color. Contact lenses or dentures may become permanently stained. </item>
                                 <item>
                                    <content styleCode="bold">diarrhea.</content> A type of diarrhea called <content styleCode="italics">Clostridioides difficile</content>âassociated diarrhea (CDAD) may occur during or after taking antibiotics, including PRIFTIN. The severity of CDAD can range from mild diarrhea to severe diarrhea that may cause death (fatal colitis). Tell your doctor right away if you have diarrhea while you take or after you stop taking PRIFTIN.</item>
                                 <item>
                                    <content styleCode="bold">worsening of a condition called porphyria.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">The most common side effects of PRIFTIN include:</content> allergic reactions and flu-like symptoms; abnormalities such as low red blood cells, low white blood cells, coughing up blood, cough, excessive number of platelets in the blood, increased sweating, high liver function tests, back pain, rash, decreased appetite, joint pain, increased blood urea, and headache.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of PRIFTIN. For more information, ask your doctor or pharmacist.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">How should I store PRIFTIN?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store PRIFTIN at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C). </item>
                                 <item>Keep PRIFTIN dry and away from heat.</item>
                                 <item>Keep PRIFTIN and all medicines out of reach of children. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">General information about the safe and effective use of PRIFTIN.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PRIFTIN for a condition for which it was not prescribed. Do not give PRIFTIN to other people, even if they have the same symptoms you have. It may harm them.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="6">This Medication Guide summarizes the most important information about PRIFTIN. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about PRIFTIN that is written for healthcare professionals. </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">What are the ingredients in PRIFTIN?</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">Active ingredient:</content> rifapentine</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">
                              <content styleCode="bold">Inactive ingredients:</content> calcium stearate, disodium EDTA, FD&amp;C Blue No. 2 aluminum lake, hydroxypropyl cellulose, hypromellose USP, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, propylene glycol, sodium ascorbate, sodium lauryl sulfate, sodium starch glycolate, synthetic red iron oxide, and titanium dioxide </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="6">Manufactured by: sanofi-aventis U.S. LLC, Morristown, NJ 07960<br/>For more information, go to www.sanofi.us or call 1-800-633-1610, and select option 1.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250521"/>
            </section>
         </component>
         <component>
            <section>
               <id root="1376758c-04f6-4f92-8be4-675f5088b815"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 150 mg Tablet Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 0088-2102-24</paragraph>
                  <paragraph>PRIFTIN<sup>Â®</sup>
                     <br/>RIFAPENTINE<br/> 150 mg per tablet</paragraph>
                  <paragraph>Dispense with Medication Guide</paragraph>
                  <paragraph>24 Tablets<br/> Three 8-Tablet <br/>Blister Strips</paragraph>
                  <paragraph>sanofi</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250521"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 150 mg Tablet Blister Pack Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="3a64fb70-b85e-43d9-8bcd-7e893f568ae1-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>